Anti-pneumococcal antibody levels at baseline and GMFR at weeks 4 and 12 after PCV-13 vaccination
| Antigen | UPA 15 mg QD | UPA 30 mg QD | ||||
| Baseline, µg/mL * (N=83) | Week 4 GMFR (95% CI) (N=83) | Week 12 GMFR (95% CI) (N=79) | Baseline, µg/mL* (N=23) | Week 4 GMFR (95% CI) (N=23) | Week 12 GMFR (95% CI) (N=22) | |
| 1 | 0.4 | 7.9 (6.1 to 10.2) | 8.1 (6.2 to 10.6) | 0.4 | 6.5 (4.0 to 10.7) | 6.5 (3.9 to 10.9) |
| 3 | 0.7 | 2.6 (2.1 to 3.2) | 2.3 (1.8 to 2.8) | 0.4 | 2.3 (1.5 to 3.5) | 2.2 (1.5 to 3.4) |
| 4 | 0.2 | 5.6 (4.3 to 7.4) | 5.2 (3.9 to 6.9) | 0.1 | 3.8 (2.3 to 6.4) | 3.4 (2.0 to 5.8) |
| 5 | 2.2 | 1.9 (1.5 to 2.4) | 1.8 (1.5 to 2.3) | 2.6 | 1.6 (1.1 to 2.4) | 1.6 (1.0 to 2.4) |
| 6B | 0.5 | 4.5 (3.3 to 6.1) | 3.9 (2.8 to 5.4) | 0.4 | 3.1 (1.7 to 5.5) | 3.3 (1.7 to 6.1) |
| 7F | 0.9 | 3.6 (2.8 to 4.5) | 3.3 (2.6 to 4.3) | 1.1 | 2.8 (1.8 to 4.4) | 3.0 (1.9 to 4.9) |
| 9V | 0.5 | 5.7 (4.3 to 7.6) | 6.2 (4.6 to 8.3) | 0.4 | 2.8 (1.6 to 4.8) | 2.9 (1.6 to 5.1) |
| 14 | 1.6 | 3.0 (2.4 to 3.7) | 2.8 (2.2 to 3.6) | 1.2 | 2.4 (1.6 to 3.7) | 2.4 (1.5 to 3.8) |
| 18C | 1.6 | 4.5 (3.5 to 5.8) | 4.4 (3.4 to 5.7) | 1.3 | 3.2 (2.0 to 5.2) | 3.5 (2.2 to 5.7) |
| 19A | 8.6 | 1.5 (1.3 to 1.7) | 1.4 (1.2 to 1.7) | 9.2 | 1.1 (0.8 to 1.5) | 1.2 (0.9 to 1.5) |
| 19F | 1.7 | 2.3 (1.8 to 2.8) | 2.2 (1.8 to 2.7) | 1.6 | 2.3 (1.5 to 3.5) | 2.0 (1.3 to 3.0) |
| 23F | 0.7 | 4.3 (3.3 to 5.7) | 4.1 (3.0 to 5.4) | 0.7 | 3.1 (1.9 to 5.2) | 3.3 (1.9 to 5.7) |
Patients with non-missing baseline and at least one post-baseline value were included in the analysis.
*Baseline geometric mean antibody levels among patients with available week 4 data.
CI, confidence interval; GMFR, geometric mean fold rise; PCV-13, pneumococcal 13-valent conjugate vaccine (Diphtheria CRM197 Protein); QD, once daily; UPA, upadacitinib.